Physician profile
Kate Lee
NPI 1619130895
$5,693.89
in general payments reported to CMS, 2019-2025
27 companies · $995 in 2025
The $995 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $142 · 2021: $365 · 2022: $1,219 · 2023: $1,300 · 2024: $900 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,170 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,169.71 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,277.76 | 2019-2025 | Clareon, Rocklatan, Rhopressa |
| Johnson & Johnson Surgical Vision, INC. | $613.12 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Abbvie INC. | $520.70 | 2022-2025 | |
| Biotissue Holdings INC. | $406.96 | 2021-2023 | |
| Bausch & Lomb Americas INC. | $318.93 | 2023-2025 | Envista Mx60 Iol, Ic-8 Apthera Iol, Xiidra |
| Sun Pharmaceutical Industries INC. | $265.15 | 2023-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $241.45 | 2019-2023 | |
| Rxsight INC | $220.17 | 2021-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Allergan, INC. | $194.43 | 2020-2022 | |
| Ocular Therapeutix, INC. | $190.03 | 2019-2025 | Dextenza |
| Aerie Pharmaceuticals, INC. | $181.45 | 2019-2021 | |
| Harrow Eye, LLC | $157.79 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $155.68 | 2025 | Xdemvy |
| Horizon Therapeutics Plc | $141.08 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $135.46 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $112.64 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $104.45 | 2019 | |
| Amgen INC. | $92.91 | 2025 | Tepezza |
| Astellas Pharma US INC | $74.21 | 2023-2025 | Izervay |
| New World Medical,INC. | $69.67 | 2023 | |
| Carl Zeiss Meditec, INC. | $69.56 | 2023 | |
| Thea Pharma INC. | $40.32 | 2024-2025 | Iyuzeh |
| Maculogix, INC. | $33.71 | 2021 | |
| Oyster Point Pharma, INC. | $23.87 | 2023 | Tyrvaya |
| Boston Scientific Corporation | $18.71 | 2022 | |
| Dompe US, INC. | $17.10 | 2025 | Oxervate |
| Tearlab Corp | $16.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.